|
|
|
|
|
|
by wolfgke
3545 days ago
|
|
|
> We could also reduce the cost of bringing new therapies to market by having the FDA say "if your drug is approved by the EU, you can sell it in the US" as per S. 2388 But what reason does the pharmaceutical company have to reduce the drug price in this case if it has a patent (i.e. a monopoly to dictate the price) instead of simply having more profit because of these (potential) changes in regulations? |
|
|